Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Photodynamic therapy and thermal laser photocoagulation

2 evidence topics · 2 sources

Historical role of verteporfin photodynamic therapy

“In 2000 photodynamic therapy with verteporfin (PDT-V) was approved by the United States' Food and Drug Administration for the treatment of subfoveal CNV due to AMD.” (opens the source at this quote in a new tab)

“PDT-V alone has been shown in a large number of cases to require retreatments every 3 months.” (opens the source at this quote in a new tab)

National Eye Institute description of photodynamic therapy

“Photodynamic therapy (PDT) is a much less common treatment for wet AMD that doctors sometimes use along with anti-VEGF injections.” (opens the source at this quote in a new tab)

“a light-sensitive medicine called verteporfin that "turns on" when hit by a specific type of laser (sometimes called a cold laser)” (opens the source at this quote in a new tab)